Table 3.

Accuracy results based on ISO 15197:2013 criteria, results within consensus error grid (CEG) zones A and B, results within surveillance error grid zones with “no risk” or “slight lower risk”, relative bias according to Bland and Altman, and calculated insulin dosing error

System	User	Results within				Relative bias	Calculated insulin dosing error
		±15 mg/dl/± 15%	CEG zones A + B	SEG zones
				No risk	Slight, lower risk		Median (50th percentile)	99% ranges between the 0.5th and 99.5th percentile
				Risk score
				0–0.5	> 0.5–1.0
		%	%	n		%	Units
A	Lay-users	96	100	100	0	− 7.6	− 0.9	− 2.7 to − 0.1
	Study personnel	99	100	197	3	− 6.8	− 0.8	− 2.4 to 0.0
B	Lay-users	100	100	100	0	− 2.2	− 0.3	− 1.0 to + 0.3
	Study personnel	100	100	200	0	− 2.2	− 0.2	− 1.0 to + 0.2
C	Lay-users	98	100	97	3	+ 2.8	+ 0.3	− 0.6 to + 1.4
	Study personnel	99.5	100	198	2	+ 1.6	+ 0.2	− 0.7 to +1.4
D	Lay-users	92	100	97	3	− 5.6	− 0.6	− 2.4 to +0.6
	Study personnel	96	100	193	7	− 5.3	− 0.7	− 2.5 to + 0.3

Results are shown for measurements performed by lay-users (n = 100) and by study personnel (N = 200) when evaluated by using the manufacturer’s comparison method (hexokinase for system A, glucose oxidase for systems B, C, and D)